TNGX Stock Summary and Trading Ideas (Tango Therapeutics | NASDAQ:TNGX)

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Tango Therapeutics trades on the NASDAQ stock market under the symbol TNGX.

As of April 10, 2026, TNGX stock price declined to $19.95 with 1,631,153 million shares trading.

TNGX has a beta of 1.15, meaning it tends to be more sensitive to market movements. TNGX has a correlation of 0.02 to the broad based SPY ETF.

TNGX has a market cap of $2.69 billion. This is considered a Mid Cap stock.

Last quarter Tango Therapeutics reported $0 in Revenue and -$.29 earnings per share. This fell short of revenue expectation by $-500,400 and exceeded earnings estimates by $.03.

In the last 3 years, TNGX traded as high as $22.20 and as low as $1.03.

The top ETF exchange traded funds that TNGX belongs to (by Net Assets): IWM, XBI, VTI, IWN, IBB.

TNGX has outperformed the market in the last year with a return of +1440.5%, while the SPY ETF gained +30.9%. In the last 3 month period, TNGX beat the market returning +69.8%, while SPY returned -1.8%. However, in the most recent 2 weeks TNGX has underperformed the stock market by returning +3.6%, while SPY returned +7.2%.

TNGX support price is $19.91 and resistance is $21.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TNGX shares will trade within this expected range on the day.